MedTrace Logo

Adding Dexmedetomidine to Mannitol to Attenuate the Increase of Intracranial Pressure

NCT07064720 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-01-21

No results posted yet for this study

Summary

Dexmedetomidine is a potent alpha-2 adrenergic receptor agonist. In addition, dexmedetomidine-induced stimulation of the postsynaptic alpha-2 adrenergic receptor on the cerebral blood vessels can cause cerebral vasoconstriction and decrease cerebral blood flow

Conditions

  • Dexmedetomidine

Interventions

DRUG

Dexmedetomidine with Mannitol

receive 1 mcg/kg of dexmedetomidine added to 0.4 mcg/kg of mannitol

DRUG

Mannitol (20%)

receive 0.5 g/kg of mannitol

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-12
Primary Completion
2025-12-22
Completion
2026-01-15

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07064720 on ClinicalTrials.gov